Back to Search
DAVID VAN ECHO, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1356327662Individual
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
D0058924(MD)
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
D0058924(MD)
Research & Publications (17)
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
PMID 19117293·Laryngoscope·2009
7-preclinical
The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method.
PMID 18064568·Breast Cancer Res Treat·2008
8-other
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.
PMID 17562815·J Exp Med·2007
7-preclinical
The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
PMID 15726515·Semin Oncol·2004
3-trial
Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer.
PMID 12810463·Arch Otolaryngol Head Neck Surg·2003
4-observational
Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors.
PMID 12607837·Med Phys·2003
3-trial
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug.
PMID 12736763·Cancer Chemother Pharmacol·2003
3-trial
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
PMID 16258479·Clin Adv Hematol Oncol·2003
5-case
Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication.
PMID 12829680·J Clin Oncol·2003
8-other
Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer.
PMID 12827298·Cancer Chemother Pharmacol·2003
3-trial
Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
PMID 12124336·Cancer Res·2002
7-preclinical
Pleurx tunneled catheter in the management of malignant ascites.
PMID 11287517·J Vasc Interv Radiol·2001
8-other
Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck.
PMID 11169937·Cancer·2001
3-trial
Phase I study of docetaxel and topotecan in patients with solid tumors.
PMID 11138457·Cancer Chemother Pharmacol·2000
3-trial
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors.
PMID 10986062·J Clin Oncol·2000
3-trial
The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
PMID 10758304·Int J Radiat Oncol Biol Phys·2000
8-other
Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma.
PMID 10741706·Clin Cancer Res·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 508 FULTON ST
DURHAM, NC 27705 - Phone
- (304) 268-5265
Quick Facts
- NPI
- 1356327662
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 17
Are you this provider?
Claim Your Profile